First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A
Sign Up to like & getrecommendations! Published in 2017 at "Haemophilia"
DOI: 10.1111/hae.13246
Abstract: N8‐GP (turoctocog alfa pegol) is an extended half‐life glycoPEGylated recombinant factor VIII (FVIII) product developed for the prevention and treatment of bleeds in haemophilia A patients. read more here.
Keywords: glycopegylated recombinant; extended half; life glycopegylated; haemophilia first ... See more keywords